Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

NCT02101684 | Terminated Phase 2

• 2 other identifiers: GETHI 2013-012013-003128-35
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 9

Brief Summary

Granulosa Cell ovarian carcinoma is an infrequent subtype of neoplasia well differentiated from epithelial tumors. They account for 5% of all ovarian malignancies and, with an incidence of 0.4-1.2 cases per 100000 habitants, is considered as a rare disease. Though most cases are identified at initial stages and can be cured through surgical resection, distant recurrences have been documented even 10 years after resecting the primary tumor. At advanced stage it is a lethal disease. Unfortunately because of the low incidence of this disease randomized clinical trials are lacking. In fact current evidence for treatment is provided by case reports, retrospective studies and phase II clinical trials performed one decade ago. Orteronel, a novel, orally active, selective inhibitor of 17,20-lyase, is being developed as an endocrine therapy for relevant hormone-sensitive cancers such as prostate cancer and breast cancer. Orteronel is expected to suppress sex hormone levels in both circulation and relevant hormone-dependent malignant tissue. Since sex hormone overproduction has been demonstrated in granulosa cell ovarian tumors and seems to play a major role in this disease, this study will assess the efficacy or orteronel treating such tumors.

Conditions

Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

Keywords

Orteronel, Granulosa Cell Tumour

Outcome Measures

Primary Outcomes (1)

• Clinical benefit at 6 months

  Clinical benefit is defined as the average of patients with radiological response (partial or complete) plus stable disease longer than 6 months by RECIST 1.1 criteria

  6 months

Secondary Outcomes (5)

• Overall Response Rate

  Every 8 weeks, during 6 months

• Progression free survival

  Every 8 weeks, during 6 months

• Overall Survival

  Every 12 weeks, untill death

• Reduction of sex hormones production.

  Every 8 weeks, during 6 months

• Toxicity profile

  Every 4 weeks, untill end of treatment (6 months estimated)

Study Arms (1)

Orteronel 300mg b.i.d.

EXPERIMENTAL

Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.

Drug: Orteronel 300mg BID

Interventions

Orteronel 300mg BID DRUG

Orteronel 300mg b.i.d.

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary written informed consent.
• Patients, even if surgically sterilized who:
• Agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or
• Agree to completely abstain from intercourse.
• Patients 18 years or older.
• Screening clinical laboratory values as specified below:
• Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be \<=2.5 X ULN.
• Total bilirubin \<=1.5 X ULN.
• Estimated creatinine clearance using the Cockcroft-Gault formula must be \>40 mL/minute.
• Absolute neutrophil count (ANC) \>=1500/mcL and platelet count \>=100,000/mcL.
• Histologically confirmed granulosa cell ovarian tumor with locally advanced non-resectable or metastatic disease, measurable or evaluable by RECIST.
• Availability of sufficient biopsy material to confirm the malignant diagnosis of granulosa cell ovarian tumor by a centralized pathologist and to perform the determine the FOXL2 402C mutation → G (C134W). However study entry will be allowed based just on the histological local diagnosis.
• Life expectancy \>=12 weeks
• Screening calculated ejection fraction of greater than or equal to normal by multiple gated acquisition (MUGA) scan, or by echocardiogram (ECHO).
• Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 4 weeks before first dose of study drug/randomization.

You may not qualify if:

• History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of Grade \> 2 (NCI CTCAE, version 4.02)(56), thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
• New York Heart Association Class III or IV heart failure.
• ECG abnormalities of:
• Q-wave infarction, unless identified 6 or more months prior to screening
• QTc interval \> 460 msec
• Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum ?- human chorionic gonadotropin (?-hCG) pregnancy test result obtained during screening.
• Patient has received other investigational drugs within 28 days before enrollment
• Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy.
• Prior therapy with orteronel, ketoconazole, abiraterone, aminoglutethimide or enzalutamide.
• Patients received radical radiotherapy \<= 4 weeks before starting the study treatment or who have not recovered from the toxicities of radiotherapy. Palliative radiotherapy of painful bone lesions is allowed up to 14 days before the start of study treatment.
• Known hypersensitivity to compounds related to orteronel or to orteronel excipients.
• Uncontrolled hypertension despite appropriate medical therapy (BP of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the Screening visit). Note: patients may be rescreened after adjustment of antihypertensive medications.
• Known active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator?s opinion, potentially interfere with participation in this study.
• Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel.
• Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of orteronel, including difficulty swallowing tablets.

Sponsors & Collaborators

• Grupo Español de Tumores Huérfanos e Infrecuentes: lead
• Takeda: collaborator

Study Sites (9)

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, 07198, Spain

Location

Complexo Hospitalario Universitario de Santiago

Santiago de Compostela, La Coruña, 15706, Spain

Location

Hospital Universitario Fundación Alcorcón

Alcorcón, Madrid, 28922, Spain

Location

Complejo Hospitalario de Navarra

Pamplona, Navarre, 31008, Spain

Location

Hospital Del Mar

Barcelona, 08003, Spain

Location

Complejo Hospitalario Regional Reina Sofía

Córdoba, 14004, Spain

Location

Hospital Universitario La Paz

Madrid, 28046, Spain

Location

Hospital Universitario Madrid Sanchinarro

Madrid, 28050, Spain

Location

Hospital Universitari I Politècnic La Fe

Valencia, 46026, Spain

Location

Related Publications (1)

• Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, Rubio MJ, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Barquin A, Grande E, Alia EG, Sevillano E, Bover I, Grazioso TP, Sanchez-Escribano R, Hurtado A, Navarro P, Rodriguez-Moreno JF. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). Clin Transl Oncol. 2025 Jul;27(7):3223-3231. doi: 10.1007/s12094-024-03827-4. Epub 2024 Dec 30.

  PMID: 39738931 DERIVED

MeSH Terms

Conditions

Neoplasm Metastasis; Granulosa Cell Tumor

Interventions

orteronel; BID protein, human

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Sex Cord-Gonadal Stromal Tumors; Neoplasms, Gonadal Tissue; Neoplasms by Histologic Type; Ovarian Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Jesús García-Donas, MD

  Hospital Universitario Madrid Sanchinarro

  STUDY DIRECTOR

• Alicia Hurtado, MD

  Hospital Universitario Fundación Alcorcón

  PRINCIPAL INVESTIGATOR

• Juan Cueva, MD

  COMPLEXO HOSPITALARIO UNIVERSITARIO DE SANTIAGO

  PRINCIPAL INVESTIGATOR

• Laia Garrigos, MD

  Hospital del Mar

  PRINCIPAL INVESTIGATOR

• María Jesús Rubio, MD

  COMPLEJO HOSPITALARIO REGIONAL REINA SOFÍA

  PRINCIPAL INVESTIGATOR

• Andrés Redondo, MD

  Hospital Universitario La Paz

  PRINCIPAL INVESTIGATOR

• Isabel Bover, MD

  Hospital Son Llatzer

  PRINCIPAL INVESTIGATOR

• Nuria Lainez, MD

  Complejo Hospitalario de Navarra

  PRINCIPAL INVESTIGATOR

• Ana Santaballa, MD

  Hospital Universitario La Fe

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 26, 2014
• First Posted: April 2, 2014
• Study Start: June 1, 2014
• Primary Completion: January 11, 2017
• Study Completion: January 11, 2017
• Last Updated: March 5, 2018

Record last verified: 2018-03

Locations

ES (9)